Other
Hepatotoxicity
General Population:Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months [see Warnings and Precautions ( 5.1)] .
Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When divalproex sodium delayed-release capsules are used in this patient group, they should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.
Patients with Mitochondrial Disease:There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase γ (POLG) gene (e.g. Alpers Huttenlocher Syndrome). Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder [see Contraindications ( 4)] . In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release capsules should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with divalproex sodium delayed-release capsules for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice [see Warnings and Precautions ( 5.1)] .
Fetal Risk
Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following in uteroexposure.
Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception [see Contraindications ( 4)] . Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.
Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used[see Warnings and Precautions ( 5.2, 5.3, 5.4)] .
A Medication Guide describing the risks of valproate is available for patients [see Patient Counseling Information ( 17)] .
Pancreatitis
Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated [see Warnings and Precautions ( 5.5)] .
Divalproex sodium delayed-release capsules, USP are for oral administration.
Divalproex sodium delayed-release capsules, USP contain specially coated particles of divalproex sodium equivalent to 125 mg of valproic acid in a hard gelatin capsule.
The following serious adverse reactions are described below and elsewhere in the labeling:
- Hepatic Failure [see Warnings and Precautions ( 5.1)]
- Birth Defects [see Warnings and Precautions ( 5.2)]
- Decreased IQ and Neurodevelopmental Disorders Following in uteroExposure [see Warnings and Precautions ( 5.3)]
- Pancreatitis [see Warnings and Precautions ( 5.5)]
- Hyperammonemic Encephalopathy [see Warnings and Precautions ( 5.6, 5.9, 5.10)]
- Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.7)]
- Bleeding and Other Hematopoietic Disorders [see Warnings and Precautions ( 5.8)]
- Hypothermia [see Warnings and Precautions ( 5.11)]
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions [see Warnings and Precautions ( 5.12)]
- Serious Dermatologic Reactions [see Warnings and Precautions (5.13)]
- Angioedema [see Warnings and Precautions ( 5.14)]
- Somnolence in the Elderly [see Warnings and Precautions ( 5.16)]
- Do notchange your dose of divalproex sodium delayed-release capsules without talking to your healthcare provider.
- Divalproex sodium delayed-release capsules may be swallowed whole or the divalproex sodium delayed-release capsules may be opened and the contents mixed into soft food such as applesauce or pudding. The sprinkles are flavorless.
- Immediately take the medicine after mixing it with soft food. Do notchew the divalproex sodium delayed-release capsules and food mixture. Do notstore the mixture for future use. Mix the divalproex sodium delayed-release capsules with soft food each time, right before it is taken.
- If you have any questions, contact your healthcare provider or pharmacist. Keep all of your healthcare provider's appointments as scheduled.
- Divalproex sodium delayed-release capsules
- soft food such as applesauce or pudding
- teaspoon
- small cup or bowl
- water
- Store divalproex sodium delayed-release capsules at 20°C to 25°C (68°F to 77°F)
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Overdosage with valproate may result in somnolence, heart block, deep coma, and hypernatremia. Fatalities have been reported; however patients have recovered from valproate levels as high as 2,120 mcg/mL.
In overdose situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. The benefit of gastric lavage or emesis will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output.
Naloxone has been reported to reverse the CNS depressant effects of valproate over dosage. Because naloxone could theoretically also reverse the antiepileptic effects of valproate, it should be used with caution in patients with epilepsy.
Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:
Divalproex sodium, USP occurs as a white powder with a characteristic odor.
Each divalproex sodium delayed-release capsules, USP intended for oral administration contains divalproex sodium equivalent to 125 mg of valproic acid. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, FD &C blue # 1, gelatin, hypromellose, methacrylic acid copolymer dispersion, microcrystalline cellulose spheres, sodium lauryl sulfate, talc, titanium dioxide and triethyl citrate. Each capsule is printed with black pharmaceutical ink which contains: ammonia solution, butyl alcohol, dehydrated alcohol, ferrosoferric oxide, isopropyl alcohol, propylene glycol, potassium hydroxide, purified water and shellac.
The Product meets USP Dissolution Test 4.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatotoxicity
Warn patients and guardians that nausea, vomiting, abdominal pain, anorexia, diarrhea, asthenia, and/or jaundice can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly [see Warnings and Precautions ( 5.1)] .
Pancreatitis
Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly [see Warnings and Precautions ( 5.5)] .
Birth Defects, Decreased IQ,and Neurodevelopmental Disorders
Inform pregnant women and women of childbearing potential (including girls beginning the onset of puberty) that use of valproate during pregnancy increases the risk of birth defects, decreased IQ, and neurodevelopmental disorders in children who were exposed in utero[see Warnings and Precautions ( 5.2, 5.3, 5.4) and Use in Specific Populations ( 8.1)] . Advise women to use effective contraception while taking valproate. When appropriate, counsel these patients about alternative therapeutic options. This is particularly important when valproate use is considered for a condition not usually associated with permanent injury or death such as prophylaxis of migraine headache [see Contraindications ( 4)] .
Pregnancy Registry
Advise women of childbearing potential to discuss pregnancy planning with their doctor and to contact their doctor immediately if they think they are pregnant.
Encourage women who are taking divalproex sodium delayed-release capsules to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 or visit the website, http://www.aedpregnancyregistry.org/ [see Use in Specific Populations ( 8.1)] .
Suicidal Thinking and Behavior
Counsel patients, their caregivers, and families that AEDs, including divalproex sodium delayed-release capsules may increase the risk of suicidal thoughts and behavior and to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to the healthcare providers [see Warnings and Precautions ( 5.7)] .
Hyperammonemia
Inform patients of the signs and symptoms associated with hyperammonemic encephalopathy and to notify the prescriber if any of these symptoms occur [see Warnings and Precautions ( 5.9, 5.10)] .
CNS Depression
Since valproate products may produce CNS depression, especially when combined with another CNS depressant (e.g., alcohol), advise patients not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions
Instruct patients that a fever associated with other organ system involvement (rash, lymphadenopathy, etc.) may be drug-related. Advise patients to report such reactions to a healthcare provider immediately [see Warnings and Precautions ( 5.12)].
Serious Dermatologic Reactions
Advise patients of the early signs and symptoms of severe cutaneous adverse reactions and to report any occurrence immediately to a healthcare provider [see Warnings and Precautions ( 5.13)] .
Angioedema
Advise patients to discontinue divalproex sodium delayed-release capsules and seek immediate medical care if they develop signs or symptoms of angioedema, such as facial, perioral, or upper airway swelling [see Warnings and Precautions ( 5.14)] .
Medication Residue in the Stool
Instruct patients to notify their healthcare provider if they notice a medication residue in the stool [see Warnings and Precautions ( 5.20)] .
Instructions for Use
Divalproex Sodium (dye val' proe ex soe' dee um)
Delayed-Release Capsules, USP
for oral use
Read the Medication Guide and this Instructions for Use that come with divalproex sodium delayed-release capsules for the most important information you need to know before taking divalproex sodium delayed-release capsules for the first time, and each time you get a refill. This information does not take the place of talking to your healthcare provider about your medical treatment or condition.
Important information
Take divalproex sodium delayed-release capsules exactly as your healthcare provider tells you. Your healthcare provider will tell you how much divalproex sodium delayed-release capsules to take and when to take it.
Supplies needed:
Preparing and taking divalproex sodium delayed-release capsules with soft foods:
Storing divalproex sodium delayed-release capsules
Keep divalproex sodium delayed-release capsules and all medicines out of the reach of children.
Repackaged and Distributed By:
Remedy Repack, Inc.
625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
This Instructions for Use has been approved by the U.S Food and Drug Administration.
Repackaged and Distributed By:
Remedy Repack, Inc.
625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762